Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » OsangHealthcare Gets CE Mark for SARS-CoV-2 Detection Kit

OsangHealthcare Gets CE Mark for SARS-CoV-2 Detection Kit

Mar 04, 2020
|
staff reporter

This article has been updated to clarify the partnership between EliTech and OsangHealthcare.

NEW YORK — Italian diagnostics firm EliTech Group said on Tuesday that South Korea's OsangHealthcare has received CE marking for its GeneFinder COVID-19 RealAmp Kit for the detection of SARS-CoV-2.

The kit is designed to detect the RdRP gene, E gene, and N gene of the virus, according to EliTech. It runs on EliTech's Elite InGenius sample-to-result platform, as well as all major thermocyclers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Stricter Vaccine Standards

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Another Trial to Ramp Up

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Few Billion More

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Sequencing

  1. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

  2. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  3. Genome Sequencing Boosts Diagnostic Yield in Children With Unexplained Medical Complexity

  4. JP Morgan Downgrades Illumina to Neutral on Grail Deal

  5. Illumina to Acquire Grail for $8B in Cash and Stock

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.